Association of COVID‐19 with skin diseases and relevant biologics: A cross‐sectional study using nationwide claim data in South Korea

By Cho SI
Published September 3, 2020

Key Takeaways

Through analyzing a nationwide claim dataset relevant to coronavirus disease (COVID‐19) in South Korea, researchers intended to determine if there is a connection between COVID‐19 and skin diseases or biologics. This dataset comprised insurance claim data prior to and during COVID‐19 treatment and clinical outcomes. The dataset comprised a total of 234,427 (M/F: 111,947/122,480) individuals who had undergone COVID‐19 testing. Seven thousand five hundred ninety (3.2%) of them were confirmed as COVID‐19 (+) and 227 (3.0%) confirmed patients died. According to findings, underlying skin diseases did not seem to increase COVID-19 susceptibility or COVID-19 mortality. During the COVID‐19 pandemic, biologics for dermatological conditions could be used continuously taking into account the risks and benefits.

Read the full article on British Journal of Dermatology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter